دورية أكاديمية
Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks
| العنوان: | Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks |
|---|---|
| المؤلفون: | Berenbaum, F., Langford, R., Perrot, S., Miki, K., Blanco, F.J., Yamabe, T., Isogawa, N., Araki, S., Junor, R., Carey, W., Viktrup, L., West, C.R., Brown, M.T., Verburg, K. |
| المصدر: | In Osteoarthritis and Cartilage April 2020 28 Supplement 1:S144-S145 |
| قاعدة البيانات: | ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 10634584 |
|---|---|
| DOI: | 10.1016/j.joca.2020.02.239 |